Green Synthesis of Palladium Nanoparticles: Applications in Aryl Halide Cyanation and Hiyama Cross-Coupling Reaction Under Ligand Free Conditions
作者:Vishal Kandathil、Ramesh B. Dateer、B. S. Sasidhar、Shivaputra A. Patil、Siddappa A. Patil
DOI:10.1007/s10562-018-2369-5
日期:2018.6
in arylhalide cyanation and Hiyama cross-coupling reactions. Also, less toxic potassium hexacyanoferrate(II) trihydrate was used as cyanide source in arylhalide cyanation and Hiyama cross-coupling was performed under fluoride free condition. Both reactions proceeded well with Pd NPs under ligand free circumstances to give good to excellent yields. The Pd NPs were recovered after each reaction and
Compounds and compositons for treating C1s-mediated diseases and conditions
申请人:3-Dimensional Pharmaceuticals, Inc.
公开号:US20020037915A1
公开(公告)日:2002-03-28
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I
1
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R
1
, R
2
, R
3
, R
4
, X, Y and Z are defined in the specification.
Palladium-Catalyzed Synthesis of Arylamines from Aryl Halides and Lithium Bis(trimethylsilyl)amide as an Ammonia Equivalent
作者:Sunwoo Lee、Morten Jørgensen、John F. Hartwig
DOI:10.1021/ol016333y
日期:2001.8.1
[reaction: see text]. A simple, palladium-catalyzed method to convert aryl halides to the parent anilines using lithium bis(trimethylsilyl)amide (LiN(SiMe3)2) is reported. The reaction is catalyzed by Pd(dba)2 and P(t-Bu)3 and can be run with as little as 0.2 mol % of catalyst. The reaction is faster than competing generation of benzyne intermediates and, therefore, provides the aniline products regiospecifically
[EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
申请人:AGENCY SCIENCE TECH & RES
公开号:WO2015094119A1
公开(公告)日:2015-06-25
The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.
MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF
申请人:BOTHMANN Hendrick
公开号:US20100016288A1
公开(公告)日:2010-01-21
Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.